FDA clears Pfizer booster for older adults and certain higher-risk groups

FDA Building 1 at the agency’s White Oak campus

The Food and Drug Administration on Wednesday authorized a booster dose of Pfizer’s COVID-19 vaccine for adults 65 and older and certain younger adults at higher risk.

The authorization covers adults ages 18 through 64 at high risk of severe COVID-19, as well as adults in that age range whose work or institutional settings expose them frequently to the virus. The extra dose is authorized at least six months after the primary series.

The decision applies to the Pfizer-BioNTech vaccine. The Centers for Disease Control and Prevention is reviewing how it will recommend use of the booster.

Reporting source. Cover photograph: U.S. Food and Drug Administration, public domain.